CD274 and non-small cell lung carcinoma: The randomized phaseIII, PACIFIC trial [ClinicalTrials.gov identifier: NCT02125461] of durvalumab assequential treatment in patients with locally advanced, unresectable NSCLC whosedisease did not progress following definitive platinum-based concurrentchemoradiation showed median PFS improvement of over 11 months from time ofrandomization [16.8 months versus 5.6 months; HR 0.52 (95% CI0.42–0.65); p < 0.001], regardless of PD-L1 expression.44 The OS data are still pending.